Allan K Hansen1, Malene Flensborg Damholdt2, Tatyana D Fedorova1, Karoline Knudsen1, Peter Parbo1, Rola Ismail1, Karen Østergaard3, David J Brooks1,4,5, Per Borghammer1. 1. Dept of Nuclear Medicine & PET Centre, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark. 2. Unit of Psychooncology and Health psychology, Dept of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark. 3. Dept of Neurology, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark. 4. Division of Neuroscience, Dept of Medicine, Imperial College London, United Kingdom. 5. Division of Neuroscience, Newcastle University, United Kingdom.
Abstract
BACKGROUND: Alzheimer's disease copathology is common in PD at autopsy. In non-PD subjects with mild cognitive impairment, tau depositions can be detected using 18F-AV-1451 PET. We hypothesized that 18F-AV-1451 PET would show tau aggregation in PD with mild cognitive impairment and correlate with cognitive dysfunction. OBJECTIVES: To describe tau aggregation in PD patients. METHODS: Twenty-six PD patients and 23 controls had 18F-AV-1451 PET and neuropsychological assessment to detect mild cognitive impairment. RESULTS: Nine PD patients (35%) were identified with mild cognitive impairment. Regional analyses showed no significant differences between groups. Voxel-wise analyses showed no correlation with cognitive domain z-scores within patients. One patient with mild cognitive impairment was estimated Braak tau stage 5; all other patients were stage 0. CONCLUSION: Our results indicate that tau pathology, as detected by 18F-AV-1451, is uncommon in PD with mild cognitive impairment and shows no significant correlation with cognitive dysfunction at this stage.
BACKGROUND:Alzheimer's disease copathology is common in PD at autopsy. In non-PD subjects with mild cognitive impairment, tau depositions can be detected using 18F-AV-1451 PET. We hypothesized that 18F-AV-1451 PET would show tau aggregation in PD with mild cognitive impairment and correlate with cognitive dysfunction. OBJECTIVES: To describe tau aggregation in PDpatients. METHODS: Twenty-six PDpatients and 23 controls had 18F-AV-1451 PET and neuropsychological assessment to detect mild cognitive impairment. RESULTS: Nine PDpatients (35%) were identified with mild cognitive impairment. Regional analyses showed no significant differences between groups. Voxel-wise analyses showed no correlation with cognitive domain z-scores within patients. One patient with mild cognitive impairment was estimated Braak tau stage 5; all other patients were stage 0. CONCLUSION: Our results indicate that tau pathology, as detected by 18F-AV-1451, is uncommon in PD with mild cognitive impairment and shows no significant correlation with cognitive dysfunction at this stage.
Authors: Joseph R Winer; Anne Maass; Peter Pressman; Jordan Stiver; Daniel R Schonhaut; Suzanne L Baker; Joel Kramer; Gil D Rabinovici; William J Jagust Journal: JAMA Neurol Date: 2018-02-01 Impact factor: 18.302
Authors: Gabriel Cassinelli Petersen; Michelle Roytman; Gloria C Chiang; Yi Li; Marc L Gordon; Ana M Franceschi Journal: Curr Opin Neurol Date: 2022-04-01 Impact factor: 6.283
Authors: Marta Marquié; Eline E Verwer; Avery C Meltzer; Sally Ji Who Kim; Cinthya Agüero; Jose Gonzalez; Sara J Makaretz; Michael Siao Tick Chong; Prianca Ramanan; Ana C Amaral; Marc D Normandin; Charles R Vanderburg; Stephen N Gomperts; Keith A Johnson; Matthew P Frosch; Teresa Gómez-Isla Journal: Acta Neuropathol Commun Date: 2017-10-19 Impact factor: 7.801
Authors: David G Coughlin; Jeffrey S Phillips; Emily Roll; Claire Peterson; Rebecca Lobrovich; Katya Rascovsky; Molly Ungrady; David A Wolk; Sandhitsu Das; Daniel Weintraub; Edward B Lee; John Q Trojanowski; Leslie M Shaw; Sanjeev Vaishnavi; Andrew Siderowf; Ilya M Nasrallah; David J Irwin; Corey T McMillan Journal: Neurobiol Aging Date: 2020-08-21 Impact factor: 4.673